Availability of brain serotonin transporters in patients with restless legs syndrome

Neurology

Volumn 74, Issue 6, 2010, Pages 513-518

  Jhoo, J H ^a   Yoon, I Y ^b,c   Kim, Y K ^b   Chung, S ^b   Kim, J M ^b   Lee, S B ^d   Kim, T H ^b   Moon, S H ^b   Kim, S E ^b   Kim, K W ^b,c  

^a Kangwon National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University   (South Korea)

^d Dankook University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER I 123; CONTRAST MEDIUM; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; ISOTOPE LABELING; MALE; MEDULLA OBLONGATA; NATIONAL HEALTH ORGANIZATION; NEUROTRANSMISSION; PONS; PRIORITY JOURNAL; RATING SCALE; RESTLESS LEGS SYNDROME; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 76649099540     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181cef824     Document Type: Article

References (39)

1. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study: memory and morbidity in Augsburg elderly. Neurology 2000;54:1064-1068.
2. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000;160:2137-2141.
3. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994;17:739-743.
4. Tison F, Crochard A, Leger D, Bouee S, Lainey E, El Has-naoui A. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 2005;65:239-246.
5. Cho YW, Shin WC, Yun CH, et al. Epidemiology of restless legs syndrome in Korean adults. Sleep 2008;31:219-223.
6. Kim J, Choi C, Shin K, et al. Prevalence of restless legs syndrome and associated factors in the Korean adult population: the Korean Health and Genome Study. Psychiatry Clin Neurosci 2005;59:350-353.
7. Kim KW, Youn I-Y, Chung S, et al. Prevalence, comor-bidities and risk factors of restless legs syndrome in the Korean elderly population: the results from the Korean Longitudinal Study on Health and Aging (KLoSHA). J Sleep Res Epub 2009 Jul 21.
8. Hogl B, Kiechl S, Willeit J, et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology 2005;64:1920-1924.
9. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002;53:547-554.
10. Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004;164:196-202.
11. Trenkwalder C, Walters AS, Hening WA, et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999;14:141-145.
12. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999;52:932-937.
13. Hargrave R, Beckley DJ. Restless leg syndrome exacerbated by sertraline. Psychosomatics 1998;39:177-178.
14. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepres-sants. J Psychiatr Res 2008;43:70-75.
15. Bakshi R. Fluoxetine and restless legs syndrome. J Neurol Sci 1996;142:151-152.
16. Perroud N, Lazignac C, Baleydier B, Cicotti A, Maris S, Damsa C. Restless legs syndrome induced by citalopram: a psychiatric emergency? Gen Hosp Psychiatry 2007;29:72-74.
17. Sanz-Fuentenebro FJ, Huidobro A, Tejadas-Rivas A. Restless legs syndrome and paroxetine. Acta Psychiatr Scand 1996;94:482-484.
18. Page RL, 2nd, Ruscin JM, Bainbridge JL, Brieke AA. Restless legs syndrome induced by escitalopram: case report and review of the literature. Pharmacotherapy 2008;28: 271-280.
19. Agargun MY, Kara H, Ozbek H, Tombul T, Ozer OA. Restless legs syndrome induced by mirtazapine. J Clin Psychiatry 2002;63:1179.
20. Alex KD, Pehek EA. Pharmacologic mechanisms of seroto-nergic regulation of dopamine neurotransmission. Pharmacol Ther 2007;113:296-320.
21. Park J, Lim S, Lim J, et al. An Overview of the Korean Longitudinal Study on Health and Aging (KLoSHA). Psy-chiatr Invest 2007;4:84-95.
22. Bae JN, Cho MJ. Development of the Korean version of the Geriatric Depression Scale and its short form among elderly psychiatric patients. J Psychosom Res 2004;57: 297-305.
23. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-132.
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 suppl 20:22-33.
25. Youu S-W, Namkoong K, Kim S-J, et al. Validity of Korean version of the Mini-International Neuropsychiatric interview. Anxiety Mood 2006;2:50-55.
26. Lee JH, Lee KU, Lee DY, et al. Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries. J Geron-tol B Psychol Sci Soc Sci 2002;57:P47-P53.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
28. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
29. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42:1142-1146.
30. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007;32:86-102.
31. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161: 826-835.
32. Perrier JF, Delgado-Lezama R. Synaptic release of serotonin induced by stimulation of the raphe nucleus promotes plateau potentials in spinal motoneurons of the adult turtle. J Neurosci 2005;25:7993-7999.
33. Gebhart GF. Descending modulation of pain. Neurosci Biobehav Rev 2004;27:729-737.
34. Hentall ID, Burns SB. Restorative effects of stimulating medullary raphe after spinal cord injury. J Rehabil Res Dev 2009;46:109-122.
35. Laruelle M, Baldwin RM, Malison RT, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhu-man primates. Synapse 1993;13:295-309.
36. Innis R, Baldwin R, Sybirska E, et al. Single photon emission computed tomography imaging of monoamine re-uptake sites in primate brain with [123I]CIT. Eur J Pharmacol 1991;200:369-370.
37. Oya S, Choi SR, Hou C, et al. 2-((2-((dimethyla-mino)methyl)phenyl)thio)- 5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol 2000; 27:249-254. (Pubitemid 30314718)
38. De Win MM, Habraken JB, Reneman L, van den Brink W, den Heeten GJ, Booij J. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neu-ropsychopharmacology 2005;30:996-1005.
39. Hening WA, Walters AS, Wagner M, et al. Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep 1999;22:901-912.